Physician profile
Junaid Hashim
NPI 1013038785
$3,485.47
in general payments reported to CMS, 2019-2025
22 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $373 · 2021: $527 · 2022: $470 · 2023: $733 · 2024: $217 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $606.13 | 2019-2023 | Spravato |
| Abbvie INC. | $489.53 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $402.64 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $348.65 | 2019-2023 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $285.27 | 2021-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $244.24 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $154.86 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $147.17 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $131.01 | 2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $128.63 | 2019-2024 | Rexulti |
| Lundbeck LLC | $95.56 | 2020-2024 | Rexulti |
| Bausch Health US, LLC | $90.58 | 2020-2023 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $85.20 | 2023-2024 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $78.04 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.49 | 2020-2024 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $26.19 | 2022 | |
| Allergan, INC. | $23.45 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.14 | 2019 | |
| Neos Therapeutics, LP | $19.63 | 2019 | |
| Biogen, INC. | $17.33 | 2023 | |
| Eisai INC. | $16.38 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junaid Hashim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.